Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 178-183

  Sim, Kang ^a   Su, Alex ^a   Fujii, Senta ^b   Yang, Shu Yu ^c   Chong, Mian Yoon ^c   Ungvari, Gabor S ^d   Si, Tianmei ^e   Chung, Eun K ^f   Tsang, Hin Yeung ^c   Chan, Yiong H ^g   Heckers, Stephan ^h   Shinfuku, Naotaka ^c   Tan, Chay H ⁱ  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b KOBE UNIVERSITY   (Japan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f Seoul National University Hospital   (South Korea)

^g MINISTRY OF HEALTH   (Singapore)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antipsychotic; Asia; Comparative; Polypharmacy; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE;

ADULT; AGE; AGED; ARTICLE; CHINA; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG MEGADOSE; FEMALE; HONG KONG; HUMAN; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MULTICENTER STUDY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEX DIFFERENCE; SINGAPORE; TAIWAN;

ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 3843087475     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02102.x     Document Type: Article

References (30)

1. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (Suppl 1): S35-40.
2. Keks NA, Altson K, Hope J et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896-901.
3. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002; 28: 31-42.
4. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003; 12: 41-8.
5. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55-9.
6. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv 2000; 51: 525-7.
7. Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003; 64: 105-17.
8. Procyshyn RM, Kennedy NB, Tse G et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001; 46: 334-9.
9. Tibaldi G, Munizza C, Bollini P, Pirfo E, Punzo F, Gramaglia F. Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatr Serv 1997; 48: 213-7.
10. Kiivet RA, Llerena A, Dahl M-L et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995; 40: 467-76.
11. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28: 75-84.
12. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol 1999; 55: 685-90.
13. Dollfus S, van Os J, Petit M. Do we need a European consensus on the use of antipsychotic medication. Eur Psychiatry 1996; 11: 400-2.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Press, 1994.
15. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organisation, 1992.
16. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. Washington DC: American Psychiatric Press, 1997.
17. Inagaki A, Inada T, Fujii Y, Yagi G. Equivalent Doses of Psychotropics. Tokyo: Seiwa Shoten, 1999.
18. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8: 55-66.
19. Chong SA, Sachdev P, Mahendran R et al. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust NZ J Psychiatry 2000; 34: 988-91.
20. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323-30.
21. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002; 63: 93-4.
22. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. J Clin Psychiatry 2003; 64: 673-9.
23. Andia AM, Zisook S, Heaton RK et al. Gender differences in schizophrenia. J Nerv Ment Dis 1995; 183: 522-8.
24. Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res 1996; 22: 215-22.
25. Cernovsky ZZ, Landmark JA, O'Reilly RL. Symptom patterns in schizophrenia for men and women. Psychol Rep 1997; 80: 1267-71.
26. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-51.
27. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-81.
28. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-65.
29. Kennedy NB, Procyshyn RM. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2000; 7: 155-9.
30. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60: 425-6.